ReviewAmerican journal of translational research2026
A comprehensive review of gastrointestinal cancers: epidemiology, risk factors, diagnosis, and therapeutic strategies.
Review in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesGastrointestinal cancers, including gastric cancer, colorectal cancer (CRC), and liver cancer, represent a major global health burden. This review aims to provide an integrated overview of their epidemiology, risk factors, molecular mechanisms, diagnostic approaches, and therapeutic strategies, while highlighting recent advances and ongoing challenges.
methodsA comprehensive review of recent literature was conducted to synthesize current evidence on genetic alterations, environmental and lifestyle risk factors, infectious agents such as
resultsGastrointestinal cancers arise from complex interactions among genetic, environmental, and lifestyle-related factors. Recent progress in molecular profiling and biomarker discovery has improved understanding of tumor biology and enabled targeted and immune-based therapies. However, clinical benefits remain variable due to tumor heterogeneity, therapeutic resistance, and limitations in biomarker reliability.
conclusionsDespite significant advances, gastrointestinal cancers remain challenging to manage due to late diagnosis and inconsistent treatment responses. Future efforts should focus on improving early detection, developing robust biomarkers, and implementing integrated, precision-based therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.